Frederick Nahas v. Shore Medical Center

CourtCourt of Appeals for the Third Circuit
DecidedSeptember 18, 2020
Docket19-3433
StatusUnpublished

This text of Frederick Nahas v. Shore Medical Center (Frederick Nahas v. Shore Medical Center) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Frederick Nahas v. Shore Medical Center, (3d Cir. 2020).

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT __________

No. 19-3433 __________

FREDERICK NAHAS, M.D., Appellant

v.

SHORE MEDICAL CENTER; STEVEN P. NACHTIGALL; JEFFREY GOSIN; PEYTON DEARBORN; PETER JUNGBLUT; MEDICAL EXECUTIVE COMMITTEE; LEONARD GALLER __________

On Appeal from the United States District Court for the District of New Jersey (D.C. No. 1-13-cv-06537) Honorable Robert B. Kugler, U.S. District Judge __________

Submitted Under Third Circuit L.A.R. 34.1(a) on September 17, 2020

Before: KRAUSE, RESTREPO, and BIBAS, Circuit Judges

(Opinion filed: September 18, 2020)

__________

OPINION * __________

* This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not constitute binding precedent. KRAUSE, Circuit Judge.

Frederick Nahas appeals the District Court’s summary judgment in favor of his

employer, Shore Medical Center, its Medical Executive Committee, and various medical

officers (collectively Shore Medical), on his claims under Section 1 of the Sherman

Antitrust Act, 15 U.S.C. § 1, and 42 U.S.C. § 1981, as well as the dismissal of his breach

of contract claim under state law. For the reasons that follow, we will affirm.

A. Discussion 1

On appeal, Nahas contends first, that the District Court erred in rejecting his

antitrust claim for lack of standing; second, that the denial of his privileges by Shore

Medical constituted race discrimination; and third, that the District Court erred in

dismissing his breach of contract claim for lack of subject matter jurisdiction. We address

each argument below. 2

1. Nahas’s Sherman Act Claim

Where a private plaintiff asserts an antitrust claim, we require that, in addition to

Article III standing, he demonstrate “antitrust standing” to sue. While not jurisdictional,

that inquiry “focus[es] on the nature of the plaintiff’s alleged injury” and asks “whether it

1 Because we write only for the parties, who are familiar with the background of this case, we need not reiterate the factual or procedural history. The District Court had jurisdiction under 28 U.S.C. § 1331, and we have jurisdiction under 28 U.S.C. § 1291. We review de novo a district court’s grant of summary judgment under Rule 56. See Faush v. Tuesday Morning, Inc., 808 F.3d 208, 215 (3d Cir. 2015); Fed. R. Civ. P. 56(a). 2 The Healthcare Quality Improvement Act (HCQIA) does not immunize officials from civil rights claims, 42 U.S.C. § 11111(a)(1)(D), or actions seeking injunctive relief, Gordon v. Lewistown Hosp., 423 F.3d 184, 191 n.1 (3d Cir. 2005). We therefore address Nahas’s federal antitrust and race discrimination claims on the merits. 2 is of the type that the antitrust statute was intended to forestall.” Hartig Drug Co. v. Senju

Pharm. Co., 836 F.3d 261, 269 (3d Cir. 2016) (quoting Associated Gen. Contractors of

Cal. v. Cal. State Council of Carpenters, 459 U.S. 519, 538, 540 (1983)) (internal quotation

marks omitted); see Ethypharm S.A. Fr. v. Abbott Labs., 707 F.3d 223, 232 (3d Cir. 2013)

(citing City of Pittsburgh v. W. Penn. Power Co., 147 F.3d 256, 264 (3d Cir. 1998)).

To establish antitrust injury a plaintiff must show that the injury “reflect[s] the

anticompetitive effect either of the violation or of anticompetitive acts made possible by

the violation,” Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc., 429 U.S. 477, 489 (1977), or,

put differently, that the “challenged conduct affected the prices, quantity or quality of

goods or services” available or had a competition-reducing effect beyond the plaintiff’s

“own welfare.” Mathews v. Lancaster Gen. Hosp., 87 F.3d 624, 641 (3d Cir. 1996)

(quoting Tunis Bros. Co. v. Ford Motor Co., 952 F.2d 715, 728 (3d Cir. 1991)). In the

context of a denial of physician privileges, in particular, we have held that unless the

restriction significantly reduces the services available to patients in the area or “completely

extinguish[es] [the practitioner’s] ability to provide . . . services,” it does not constitute an

antitrust injury. Id.

Applying these principles here, it is clear that Nahas failed to make the requisite

showing. Nahas argues that Shore Medical’s denial of his application prevented him from

participating in the relevant market, thereby placing him at a competitive disadvantage.

Specifically, he asserts that he was unable to provide certain services to his hospitalized

patients and that seeking privileges elsewhere would disrupt his patient referral patterns,

and he points us to expert reports finding that the economic reality of the market makes

3 pursuing any alternatives potentially harmful to his practice. From this he suggests he

suffered “the type [of injury] that the antitrust statute was intended to forestall.” Hartig

Drug Co., 836 F.3d at 269.

We are not persuaded. Though he complains about the limitation placed by Shore

Medical on his ability to practice, that is not an injury that “affected the prices, quantity or

quality of goods or services” available to consumers or that had an anticompetitive effect

beyond Nahas’s “own welfare.” Mathews, 87 F.3d at 641. Not only does Nahas retain

general and vascular surgery privileges at Shore Medical, but he also has unrestricted

endovascular privileges at a nearby facility and is capable of applying for similar privileges

elsewhere. The restriction of Nahas’s endovascular privileges thus does not “completely

extinguish [his] ability to provide . . . services” and bar him from the relevant market, nor

does it deny patients access to services as consumers. Id.

Even drawing “[a]ll reasonable inferences . . . in favor of the nonmoving party,” as

we must on summary judgment, there was insufficient evidence of an antitrust injury.

Goldenstein v. Repossessors Inc., 815 F.3d 142, 146 (3d Cir. 2016) (internal quotation

marks omitted); see Fed. R. Civ. P. 56(a). The District Court therefore did not err in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc.
429 U.S. 477 (Supreme Court, 1977)
Hedges v. Musco
204 F.3d 109 (Third Circuit, 2000)
Ethypharm S.A. France v. Abbott Laboratories
707 F.3d 223 (Third Circuit, 2013)
Kirleis v. Dickie, McCamey & Chilcote, P.C.
560 F.3d 156 (Third Circuit, 2009)
Frederico v. Home Depot
507 F.3d 188 (Third Circuit, 2007)
Matthew Faush v. Tuesday Morning
808 F.3d 208 (Third Circuit, 2015)
Heiko Goldenstein v. Repossessors Inc.
815 F.3d 142 (Third Circuit, 2016)
Hartig Drug Co Inc v. Senju Pharmaceutical Co Ltd
836 F.3d 261 (Third Circuit, 2016)
Tribune Media Company v.
902 F.3d 384 (Third Circuit, 2018)
North Sound Capital LLC v. Merck & Co Inc
938 F.3d 482 (Third Circuit, 2019)
Tunis Bros. v. Ford Motor Co.
952 F.2d 715 (Third Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Frederick Nahas v. Shore Medical Center, Counsel Stack Legal Research, https://law.counselstack.com/opinion/frederick-nahas-v-shore-medical-center-ca3-2020.